STOK

Company Overview — What Does Stoke Therapeutics, Inc. Do?

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Stoke Therapeutics, Inc. (STOK) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Edward M. Kaye and employs approximately 100 people. With a market capitalization of $1.9B, STOK is one of the notable companies in the Healthcare sector.

Stoke Therapeutics, Inc. (STOK) Stock Rating — Hold (April 2026)

As of April 2026, Stoke Therapeutics, Inc. receives a Hold rating with a composite score of 36.1/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.STOK ranks #1,857 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Stoke Therapeutics, Inc. ranks #188 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

STOK Stock Price and 52-Week Range

Stoke Therapeutics, Inc. (STOK) currently trades at $34.33. The stock lost $0.82 (2.3%) in the most recent trading session. The 52-week high for STOK is $40.22, which means the stock is currently trading -14.6% from its annual peak. The 52-week low is $5.35, putting the stock 541.7% above its annual trough. Recent trading volume was 358K shares, suggesting relatively thin trading activity.

Is STOK Overvalued or Undervalued? — Valuation Analysis

Stoke Therapeutics, Inc. (STOK) carries a value factor score of 34/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 81.16x, compared to the Healthcare sector average of 23.63x — a premium of 243%. The price-to-book ratio stands at 5.67x, versus the sector average of 2.75x. The price-to-sales ratio is 10.63x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, STOK trades at 184.23x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Stoke Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Stoke Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Stoke Therapeutics, Inc. (STOK) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 7.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 5.9% versus the sector average of -33.1%.

On a margin basis, Stoke Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -286.4% (sector: -66.1%). Net profit margin stands at -249.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 120.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

STOK Debt, Balance Sheet, and Financial Health

Stoke Therapeutics, Inc. has a debt-to-equity ratio of 19.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.28x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $83M.

STOK has a beta of 0.82, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Stoke Therapeutics, Inc. is 44/100, reflecting average volatility within the normal range for its sector.

Stoke Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Stoke Therapeutics, Inc. reported revenue of $188M and earnings per share (EPS) of $-0.12. Net income for the quarter was $25M. Gross margin was 100.0%. Operating income came in at $11M.

In FY 2025, Stoke Therapeutics, Inc. reported revenue of $184M and earnings per share (EPS) of $-0.12. Net income for the quarter was $-7M. Revenue grew 404.5% year-over-year compared to FY 2024. Operating income came in at $-21M.

In Q3 2025, Stoke Therapeutics, Inc. reported revenue of $11M and earnings per share (EPS) of $-0.65. Net income for the quarter was $-38M. Revenue grew 117.2% year-over-year compared to Q3 2024. Operating income came in at $-43M.

In Q2 2025, Stoke Therapeutics, Inc. reported revenue of $14M and earnings per share (EPS) of $-0.40. Net income for the quarter was $-23M. Revenue grew 186.0% year-over-year compared to Q2 2024. Operating income came in at $-27M.

Over the past 8 quarters, Stoke Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $5M to $188M. Investors analyzing STOK stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

STOK Dividend Yield and Income Analysis

Stoke Therapeutics, Inc. (STOK) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

STOK Momentum and Technical Analysis Profile

Stoke Therapeutics, Inc. (STOK) has a momentum factor score of 70/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

STOK vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Stoke Therapeutics, Inc. (STOK) ranks #188 out of 838 stocks based on the Blank Capital composite score. This places STOK in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing STOK against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full STOK vs S&P 500 (SPY) comparison to assess how Stoke Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

STOK Next Earnings Date

No upcoming earnings date has been announced for Stoke Therapeutics, Inc. (STOK) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy STOK? — Investment Thesis Summary

Stoke Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 23/100 flags below-average profitability. The value score of 34/100 indicates premium valuation. Price momentum is positive at 70/100, suggesting the trend favors buyers.

In summary, Stoke Therapeutics, Inc. (STOK) earns a Hold rating with a composite score of 36.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on STOK stock.

Related Resources for STOK Investors

Explore more research and tools: STOK vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare STOK head-to-head with peers: STOK vs AZN, STOK vs SLGL, STOK vs VMD.